Semaglutide is primarily recommended for adults with a body mass index (BMI) of 30 or greater, or those with a BMI of 27 or greater who also have weight-related health conditions
N Engl J Med 13:390 McGarry A, Rosanbalm S, Leinonen M et al (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinsons disease: a randomised, double-blind, placebo-controlled trial
Observed Response During Tirzepatide Phase: The data collected during the Tirzepatide phase (e.g., extent of weight loss, glycemic control achieved, presence of side effects) will inform the starting point for Retatrutide
Since constipation is a major cause of hemorrhoids, this is an important link to consider
[10] NAD+ doesnt appear to adversely interact with common medications
But alternatives exist: Lower doses Different drugs (some report fewer side effects with Mounjaro vs